The fixation time profile of linezolid changes impressively in fundamentally sick patients. The question of interest is, assuming the site of disease impacts linezolid serum fixations. About 68 sick patients treated with linezolid were incorporated. The focus time profile for linezolid was resolved to utilize the greatest deduced expectations. The objective was a boxing focus (Cmin) range of 2 and 10 mg/L. A generalized linear model (GLM) was laid out to assess potential covariates. The signs for linezolid treatment were in plunging request: peritonitis (38.2%), pneumonia (25.0%), irresistible acute respiratory distress syndrome (ARDS) (19.1%), and another non-aspiratory disease (17.7%). About 27.2 and 7.9% were subtherapeutic and harmful, separately. In the GLM, ARDS (mean: −2.1 mg/L, CI: −3.0 to −1.2 mg/L) and pneumonia (mean: −2.2 mg/L, CI: −2.8 to −1.6 mg/L) were critical (P<0.001) determinants of Cmin. Patients with ARDS (mean: 2.3 mg/L, 51.2% subtherapeutic, 0.0% toxic) and pneumonia (mean: 3.5 mg/L, 41.5% subtherapeutic, 7.7% toxic) had altogether (P<0.001) lower Cmin than those with peritonitis (mean: 5.5 mg/L, 14.4% subtherapeutic, 9.3% toxic) and other non-aspiratory contamination (mean: 5.2 mg/L, 3.3% subtherapeutic, 16.5% toxic). Linezolid serum fixations are diminished in patients with aspiratory contaminations. Future examinations should research if other linezolid edges are required in those patients due to linezolid pooling in patients’ lungs.